MIM
OTLK icon

MetLife Investment Management’s Outlook Therapeutics OTLK Stock Holding History

MetLife Investment Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,172
Closed -$145K – 2955
2023
Q2 		$145K Hold
4,172
– – ﹤0.01% 2460
2023
Q1 		$90.9K Buy
+4,172
New +$93.3K ﹤0.01% 2592

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

MetLife Investment Management's OTLK Position: Q3 2023 in Review

MetLife Investment Management sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 4,172 shares — an estimated $145K sold.

MetLife Investment Management first reported a position in OTLK in Q1 2023 and held it in 2 quarters. The position peaked at $145K in Q2 2023. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • MetLife Investment Management reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 4,172 Outlook Therapeutics shares in Q3 2023, an estimated $145K.
  • MetLife Investment Management first reported a position in Outlook Therapeutics in Q1 2023 and held it in 2 quarters.
  • MetLife Investment Management's Outlook Therapeutics position peaked at $145K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.